Assessment and Mitigation of Cardiovascular Risk for Prostate Cancer Patients: A Review of the Evidence.

IF 0.8 4区工程技术 Q4 CHEMISTRY, ANALYTICAL

Accreditation and Quality Assurance Pub Date : 2022-05-17 eCollection Date: 2022-01-01 DOI:10.1155/2022/2976811

Patrick Davey, Kyriacos Alexandrou

{"title":"Assessment and Mitigation of Cardiovascular Risk for Prostate Cancer Patients: A Review of the Evidence.","authors":"Patrick Davey, Kyriacos Alexandrou","doi":"10.1155/2022/2976811","DOIUrl":null,"url":null,"abstract":"Background: Cardiovascular disease (CVD) is a common comorbidity in patients with prostate cancer. In this review, we summarize the published literature on the association of cardiovascular risk with androgen deprivation therapy (ADT) treatment and explore the potential differences between the gonadotropin-releasing hormone (GnRH) agonists and antagonists and the molecular mechanisms that may be involved. We also provide a practical outlook on the identification of underlying CV risk and explore the different stratification tools available.Results: While not definitive, the current evidence suggests that GnRH antagonists may be associated with lower rates of certain CV events vs agonists, particularly in patients with preexisting CVD. Risk reduction strategies such as lifestyle advice, consideration of ADT modality, and comedications may help to reduce CV risk factors and improve outcomes in prostate cancer patients receiving ADT.Conclusions: Given all the data that is currently available, identification of baseline CV risk factors may be key to risk mitigation in patients with prostate cancer receiving ADT.","PeriodicalId":454,"journal":{"name":"Accreditation and Quality Assurance","volume":"13 4-5","pages":"2976811"},"PeriodicalIF":0.8000,"publicationDate":"2022-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9158798/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accreditation and Quality Assurance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2022/2976811","RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"CHEMISTRY, ANALYTICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Cardiovascular disease (CVD) is a common comorbidity in patients with prostate cancer. In this review, we summarize the published literature on the association of cardiovascular risk with androgen deprivation therapy (ADT) treatment and explore the potential differences between the gonadotropin-releasing hormone (GnRH) agonists and antagonists and the molecular mechanisms that may be involved. We also provide a practical outlook on the identification of underlying CV risk and explore the different stratification tools available.

Results: While not definitive, the current evidence suggests that GnRH antagonists may be associated with lower rates of certain CV events vs agonists, particularly in patients with preexisting CVD. Risk reduction strategies such as lifestyle advice, consideration of ADT modality, and comedications may help to reduce CV risk factors and improve outcomes in prostate cancer patients receiving ADT.

Conclusions: Given all the data that is currently available, identification of baseline CV risk factors may be key to risk mitigation in patients with prostate cancer receiving ADT.

查看原文本刊更多论文

癌症前列腺患者心血管风险的评估和减轻：证据回顾

背景心血管疾病(CVD)是前列腺癌患者常见的合并症。在这篇综述中，我们总结了已发表的关于心血管风险与雄激素剥夺治疗(ADT)相关的文献，并探讨促性腺激素释放激素(GnRH)激动剂和拮抗剂之间的潜在差异及其可能涉及的分子机制。我们还对潜在心血管风险的识别提供了一个实用的前景，并探索了不同的分层工具。结果:虽然不确定，但目前的证据表明，与激动剂相比，GnRH拮抗剂可能与某些心血管事件的发生率较低有关，特别是在既往存在心血管疾病的患者中。降低风险的策略，如生活方式建议、考虑ADT方式和药物治疗，可能有助于减少心血管危险因素，改善接受ADT的前列腺癌患者的预后。鉴于目前所有可用的数据，确定基线CV危险因素可能是降低接受ADT的前列腺癌患者风险的关键。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Accreditation and Quality Assurance 工程技术-分析化学

CiteScore

1.80

自引率

22.20%

发文量

审稿时长

6-12 weeks

期刊介绍： Accreditation and Quality Assurance has established itself as the leading information and discussion forum for all aspects relevant to quality, transparency and reliability of measurement results in chemical and biological sciences. The journal serves the information needs of researchers, practitioners and decision makers dealing with quality assurance and quality management, including the development and application of metrological principles and concepts such as traceability or measurement uncertainty in the following fields: environment, nutrition, consumer protection, geology, metallurgy, pharmacy, forensics, clinical chemistry and laboratory medicine, and microbiology.